

Monthly Market Commentary

July saw mixed global equity market performance as heavy selling in growth and technology stocks saw value, cyclical and European bourses meaningfully outperform.

Weakness within the technology landscape was largely confined to semiconductors and AI-supply chain beneficiaries, driven by profit-taking, hedge fund deleveraging and greater scrutiny over potential returns on unprecedented AI spending. Investors also contended with more energy price volatility and the prospects of higher rates as yields on US 30yr Treasuries rose to levels not seen since June 2007.

On a regional basis, Japan's Nikkei225 was the worst performer amongst developed world indices, falling 8.1% in local currencies, thanks to weakness in semiconductors and AI-related stocks. China's Shanghai Composite Index also struggled in July, down 6.4% thanks to technology weakness and energy market disruptions.

In US markets, a 21% decline in the broad-based semiconductor index, the SOX, disproportionally impacted the NASDAQ which fell 3.2% in July versus a broadly flat finish for the S&P500. Interestingly, while the Magnificent-7 complex was up strongly in July, +2.1% as a group, there were also signs of investors becoming increasingly discerning about AI returns and capex budgets even within this cohort. For example, Microsoft shares rose 15% on a well-received Q4 result buoyed by good headline AI monetization trends, measured capex commentary and FY27 guidance for positive FCF. In contrast, Meta shares dropped 8% after management 'upgraded' FY capex and opex at its Q2 results alongside underwhelming Q3 sales guidance. At the other end of the capitalisation spectrum, rate headwinds and profit-taking weighed on US small caps with the S&P600 Small Cap Index down 2% in July.

In contrast to US and Asian market weakness, European bourses delivered good performance in July, led by the UK FTSE which finished up 3.5% in local currencies thanks to outsized exposure to Financials and Energy. Germany's DAX and France's CAC also rose 2.5% and 1.3%, respectively, benefitting from having little exposure to AI-supply chain themes and supportive macro data. Given USD weakness towards the end of the month (DXY Index -1.3% in July), returns on a USD basis were even better for European bourses.

Information Technology was the biggest laggard from a sector perspective, down 4.2%, while higher oil prices helped Energy rise 12.6% for the month. Financials were also well supported, up 6.4%, thanks to higher rate backdrop, good bank results characterised by robust capital market activity and encouraging provisioning trends, and ongoing strength in insurers. Elsewhere, movements were more modest with Staples and Consumer Discretionary up approximately 2% while Utilities and Industrials fell less than 2%.

The AUD strengthened 1.4% against the USD alongside stronger commodity prices as the Bloomberg Commodity Index and WTI Oil rose 7.2% and 21.8%, respectively. The VIX fell 0.46 points to close at 15.99 while yields on 10yr US Treasuries rose 27bps to finish the month at 4.73%.

Against this backdrop the Fund delivered a return of 4.24% for the month.

The Fund gained exposure to US-based retirement and life insurer, Corebridge during the month. While the business needs to execute on its integration, we are attracted to Corebridge's large, sticky retirement annuity franchise along with a history of producing double-digit ROE and substantial capital generation. The company has been repurchasing ~\$1bn of shares annually (~7% of market cap) which at current valuation of ~0.8x Book Value makes these particularly accretive.

Water-heater maker, A.O. Smith was the biggest detractor in July after it downgraded FY26 EPS guidance by ~2% on the back of intensifying cyclical headwinds (cost inflation) at the Q2 result. While there is still elevated risk to revised guidance, we continue to hold given a solid balance sheet, strong fundamentals (~20% margins, near 100% cash conversion), and supportive valuation. The stock is currently trading on a ~6% FCF yield, struck off what we believe to be close-to-trough earnings ahead of a meaningful replacement cycle and potential recovery in depressed new housing starts. We estimate fair value is ~\$73/share with scope for the stock to potentially further benefit from any successful sale of its sub-scale China business.

We believe the most compelling way to compound clients' wealth is by utilising multiple return sources to deliver superior risk-adjusted investment outcomes.

- Long-term compounding of investor wealth
- Multiple sources of return
- Quarterly distributions
- Risk focused investment mindset



The investment process behind the Talaria Global Equity Fund Currency Hedged Complex ETF takes a high conviction, value biased approach to construct a portfolio of high quality, large cap companies from around the globe. Our unique investment methodology harnesses the benefits of consistent income generation and capital appreciation to grow investors' real wealth.


Performance as at 31 July 2026¹

	1 Month	3 Months	6 Months	1 Year	3 Years (pa)	5 Years (pa)	7 Years (pa)	10 Years (pa)	Since Inception (pa) ²
Total Return	4.24%	8.17%	10.12%	20.32%	9.27%	9.66%	9.22%	8.18%	8.14%
Avg. Market Exposure ⁴	60%	59%	56%	57%	60%	58%	58%	59%	59%

¹ Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions.
² Inception date for performance calculation is 31 December 2012.
³ Past performance is not a reliable indicator of future performance.


⁴ Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio. Since inception market exposure is calculated from 31 December 2012.

Growth of \$10,000 Since Inception⁵



⁵ Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions. Past performance is not a reliable indicator of future performance.

Annual Distributions⁶




⁶ Illustrates Distribution Returns for the Talaria Global Equity Fund Currency Hedged Complex ETF Units for the financial year ending 30 June 2026. Inception date is 31 December 2012.

Top 10 Holdings⁷

Company Name	Holding	Country	Sector	Description
Everest Group	5.1%	USA	Financials	Leading global provider of reinsurance and insurance services
Bunzl	5.0%	United Kingdom	Industrials	Multinational distribution and outsourcing business
Bayer	4.8%	Germany	Health Care	Multinational pharmaceutical and life sciences company
GSK	4.7%	United Kingdom	Health Care	One of the world's largest pharmaceutical companies
Newmont	4.5%	USA	Materials	One of the top 3 gold producers in the world
Henkel	4.4%	Germany	Consumer Staples	A multinational household products and adhesives company
Pfizer	4.2%	USA	Health Care	A research led global pharmaceutical company
Exor	4.1%	Netherlands	Financials	A diversified holding company
Roche	4.1%	Switzerland	Health Care	A global leader in cancer treatments
A.O. Smith	3.5%	USA	Industrials	A leading manufacturer of water heaters in North America


7 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised.
Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Sector Allocation⁸



8,9 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Regional Allocation⁹



* USA includes American Depositary Receipts (ADRs) listings.

Fund Snapshot

APIR Code	WFS0547AU	Inception Date	31 December 2012
Management Fee	1.20% p.a. of the net asset value of the Fund plus Recoverable Expenses	Liquidity	Daily
Recoverable Expenses	Estimated to be 0.12% of net asset value of the Fund each Financial Year	Exit Price	\$5.57090 (31 Jul 2026)
Major Platform Availability	Ausmaq, BT Panorama, CFS Edge, CFS FirstChoice, Dash, Expand, Hub24, IconIQ, IOOF Pursuit, Linear, Macquarie, Mason Stevens, Netwealth, North, Powerwrap, Praemium	Buy / Sell Spread	0.25% / 0.25%
		Distributions	Quarterly
		Minimum Investment	\$5,000

Important Information

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975 is the Responsible Entity for the Talaria Global Equity Fund Currency Hedged Complex ETF ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). This report has been prepared by Talaria Asset Management (Talaria) to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Talaria, Equity Trustees nor any of its related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. Talaria Global Equity Fund Currency Hedged Complex ETF's Target Market Determination is available [here](#). A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed. The Zenith Investment Partners (ABN 27 103 152 672, AFSL Licence 226872) ("Zenith") rating (assigned November 2025 for fund AUS0035AU) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines. The rating issued 04/2026 is published by Lionsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lionsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lionsec assumes no obligation to update. Lionsec uses objective criteria and receives a fee from the Fund Manager. Visit [lionsec.com.au](#) for ratings information and to access the full report. © 2026 Lionsec. All rights reserved. The Genium rating (assigned May 2025) presented in this document is issued by Genium Investment Partners Pty Ltd ABN 13 165 099 785, which is a Corporate Authorised Representative of Genium Advisory Services Pty Ltd ABN 94 304 403 582, AFSL 246580. The Rating is limited to "General Advice" (s766B Corporations Act 2001 (Ch)) and has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without notice. Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision in relation to this financial product(s). Genium receives a fee from the Fund Manager for researching and rating the product(s). Visit [Genium.com.au](#) for information regarding Genium's Ratings methodology. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by Talaria Asset Management. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

